Intermediate results of the observational program on the Eligard (45 mg) administration in the clinical practice
This article deals with the intermediate results of the multicentral observational program on the 6-month prodrug leuprorelin acetate (Eligard 45 mg) administration. The study objective is to confirm the efficiency and safety of the Eligard 45 mg administration in patients with the prostate cancer i...
Main Authors: | V. B. Matveev, A. S. Markova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2016-06-01
|
Series: | Onkourologiâ |
Subjects: | |
Online Access: | https://oncourology.abvpress.ru/oncur/article/view/580 |
Similar Items
-
Final results of the prospective multicenter observational program RU-EGD-NI-001 for evaluation of efficacy and tolerability of the 6-month depot Eligard 45 mg in patients with advanced prostate carcinoma in routine clinical practice of uro-oncologists in the Russian Federation
by: V. B. Matveev, et al.
Published: (2017-06-01) -
LEUPRORELIN ACETATE DEPOT (ELIGARD) IN THE TREATMENT OF PROSTATE CANCER: WHAT DO PATIENTS WIN?
by: V. B. Matveev, et al.
Published: (2014-08-01) -
LEUPRORELIN ACETATE DEPOT (ELIGARD) IN THE TREATMENT OF PROSTATE CANCER: WHAT DO PATIENTS WIN?
by: V. B. Matveev, et al.
Published: (2014-08-01) -
INTERMITTENT HORMONE THERAPY WITH ELIGARD IN PATIENTS WITH PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01) -
INTERMITTENT HORMONE THERAPY WITH ELIGARD IN PATIENTS WITH PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)